| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The molecular target of Acanthopanaxoside B is not fully characterized. As a triterpenoid saponin, it is believed to exert various biological activities, including immunomodulatory and adaptogenic effects. Saponins from Acanthopanax species are known to interact with cell membranes and modulate immune function. Further research is needed to identify its specific molecular targets and mechanisms of action.
|
|---|---|
| ln Vitro |
In vitro activity of Acanthopanaxoside B has not been extensively characterized in the available literature. As a natural triterpenoid saponin, it is expected to exhibit biological activities similar to other saponins from Acanthopanax species, including immunomodulatory, anti-inflammatory, and adaptogenic effects. The compound's unique glycosylated structure contributes to its biological properties.
|
| ln Vivo |
In vivo activity data for Acanthopanaxoside B are limited in the available literature. As a natural product isolated from Acanthopanax senticosus, a plant with traditional medicinal use as an adaptogen, the compound is being studied for its potential pharmacological effects. Further in vivo studies are needed to characterize its efficacy and safety.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Acanthopanaxoside B are not extensively documented. As a natural saponin, its biological activity is typically assessed in cell-based assays rather than cell-free enzyme assays. The compound's ability to modulate immune function or exert adaptogenic effects is evaluated using appropriate cellular models.
|
| Cell Assay |
In vitro cellular assays for Acanthopanaxoside B are performed using various cell lines to assess its biological activity. As a saponin, it may be evaluated for immunomodulatory effects using immune cells such as macrophages or lymphocytes. Cellular responses such as cytokine production, proliferation, or activation marker expression are measured following treatment with the compound.
|
| Animal Protocol |
In vivo animal experimental protocols for Acanthopanaxoside B are not extensively documented in the available literature. As a natural product research compound, in vivo studies would typically involve administration to animal models to assess immunomodulatory or adaptogenic effects. The compound would be administered via oral or parenteral routes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Acanthopanaxoside B have not been systematically characterized. The compound has a molecular weight of 1263.43 (or 1263.41) and molecular formula C61H98O27. It is a large glycosylated triterpenoid saponin. It is soluble in DMSO, pyridine, methanol, and ethanol. The compound should be stored at 2-8°C for up to 24 months.
|
| Toxicity/Toxicokinetics |
Toxicological data for Acanthopanaxoside B are not extensively reported. As a research-use natural product, its safety profile has not been formally evaluated in comprehensive toxicology studies. The compound is intended for research purposes only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that eleutheroside B exists in Acanthopanax senticosus, and relevant data is available for reference.
Acanthopanaxoside B is a triterpenoid saponin with CAS number 915792-03-9, molecular formula C61H98O27, and molecular weight 1263.43. It is isolated from Acanthopanax senticosus (Siberian ginseng). It is one of three new triterpenoid saponins (acanthopanaxosides A, B, and C) from this plant. The compound has potential immunomodulatory and adaptogenic activities and is used in pharmacological research. |
| Molecular Formula |
C61H98O27
|
|---|---|
| Molecular Weight |
1263.4146
|
| Exact Mass |
1262.629
|
| CAS # |
915792-03-9
|
| PubChem CID |
11993928
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.628
|
| LogP |
4.49
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
88
|
| Complexity |
2490
|
| Defined Atom Stereocenter Count |
32
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)[C@@]45CC[C@@]6(C(=CC[C@H]7[C@]6(CC[C@@H]8[C@@]7(CC[C@@H](C8(C)C)O[C@H]9[C@@H]([C@H]([C@H](CO9)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C)C)[C@@H]4CC(CC5)(C)C)C)O)O)O)COC(=O)C)O)O)O
|
| InChi Key |
NYFPVHPLEGGWHZ-DIUPZIBKSA-N
|
| InChi Code |
InChI=1S/C61H98O27/c1-25-36(65)40(69)44(73)51(81-25)86-48-32(24-78-26(2)63)84-50(47(76)43(48)72)80-23-31-39(68)42(71)46(75)53(83-31)88-55(77)61-18-16-56(3,4)20-28(61)27-10-11-34-58(7)14-13-35(57(5,6)33(58)12-15-60(34,9)59(27,8)17-19-61)85-54-49(37(66)29(64)22-79-54)87-52-45(74)41(70)38(67)30(21-62)82-52/h10,25,28-54,62,64-76H,11-24H2,1-9H3/t25-,28-,29-,30+,31+,32+,33-,34+,35-,36-,37-,38+,39+,40+,41-,42-,43+,44+,45+,46+,47+,48+,49+,50+,51-,52-,53-,54-,58-,59+,60+,61-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-6-(acetyloxymethyl)-3,4-dihydroxy-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~79.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7915 mL | 3.9575 mL | 7.9150 mL | |
| 5 mM | 0.1583 mL | 0.7915 mL | 1.5830 mL | |
| 10 mM | 0.0792 mL | 0.3958 mL | 0.7915 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
